Table 5. Susceptibility of Staphylococcus strains to anti-MRSA drugs.
| Drug | MIC (µg/mL) | MRSA | Staphylococcus epidermidis | Staphylococcus haemolyticus | Staphylococcus hominis | Total |
|---|---|---|---|---|---|---|
| Arbekacin | <1 | 2 | 9 | 7 | 1 | 19 |
| 2 | 1 | 1 | ||||
| Vancomycin | 1 | 2 | 1 | 1 | 4 | |
| 2 | 9 | 4 | 1 | 14 | ||
| 4 | 2 | 2 | ||||
| Teicoplanin | <2 | 2 | 4 | 1 | 1 | 8 |
| 4 | 4 | 2 | 6 | |||
| 8 | 2 | 2 | 4 | |||
| >16 | 2 | 2 | ||||
| Linezolid | <2 | 2 | 10 | 7 | 1 | 20 |
MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus.